Moderna Covid-19 vaccine trial shows 94.1% efficacy: Study
Published By : Prameya News Bureau | December 31, 2020 IST
Share
New York, Dec 31: US-based biotechnology company Moderna's Covid-19 vaccine demonstrated 94.1 per cent efficacy, showed results from the primary analysis of a phase-3 trial. The study, published in The New England Journal of Medicine, provides evidence that the vaccine, mRNA-1273, can prevent symptomatic infection. The results are similar to the first interim analysis of the study announced by Moderna in November which showed vaccine efficacy of 94.5 per cent. The new paper published on Wednesday said that among the more than 30,000 participants randomised to receive the vaccine or a placebo, 11 of those in the vaccine group developed symptomatic Covid-19 compared to 185 participants who received the placebo, demonstrating 94.1 per cent efficacy in preventing symptomatic COVID-19. Cases of severe Covid-19 occurred only in participants who received the placebo. "Our work continues. Over the next months, we'll have increasing amounts of data to better define how this vaccine works, but the results so far show a 94.1 percent efficacy. These numbers are compelling," said Lindsey Baden, an infectious diseases specialist at Brigham and Women's Hospital in the US. "And, importantly, the data suggest protection from severe illness, indicating that the vaccine could have an impact on preventing hospitalisations and deaths, at least in the first several months post-vaccination." The study enrolled 30,420 adult participants at 99 US sites, including over 600 participants enrolled at the Brigham. Eligible participants were 18 years old or older with no known history of SARS-CoV-2 infection, and whose locations or circumstances put them at appreciable risk of SARS-CoV-2 infection and/or high risk of severe Covid-19. Participants received their first injection between July 27 and October 23, 2020, followed by a second injection 28 days later. In the placebo group, 185 participants developed symptomatic Covid-19 illness; in the vaccine group, 11 participants did. Thirty participants had severe Covid-19 -- all in the placebo group, said the study. Overall, reactions to the vaccine were mild -- about half of the recipients experienced fatigue, muscle aches, joint pain and headaches, more so after the second dose,it added. "While these results are encouraging, they are limited by the short duration of follow-up so far. Longer term data from the ongoing study may allow us to more carefully evaluate the vaccine's efficacy among different groups, determine the impact on asymptomatic infection, understand when immunity wanes, and determine whether vaccines affect infectiousness," said Baden. (IANS)
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
'Mass casualties' feared as Baltimore bridge collapses after being struck by ship
Pakistan preparing to send back nearly 1 million Afghans in repatriation drive
France raises terror alert to highest after Moscow attack
Death toll in Russia terror attack rises to 133
Russian Soyuz lifts off to space with 3 astronauts
Italy condemns Moscow terror attack
Gaza peace talks yet to make headway
Cross-border terror from Pak happening at 'industry level': EAM Jaishankar
Russia terror attack: Putin vows to punish attackers as he points at Ukraine
Russia terror attack: Death toll rises to 93, 11 suspects detained
Moscow concert hall attack live updates: More than 60 reported dead
PM Modi reaches Bhutan to inaugurate hospital, meet King
Palestinian death toll from Israeli attacks on Gaza nears 32,000: Ministry
140 Palestinians killed in Israel's raid on Gaza's Shifa hospital
Antibiotics from India for use in animals seized in UK
China says its border issues with India have nothing to do with US
India infuses 50 pc additional funds to ongoing grant projects in Sri Lanka
China says its border issues with India have nothing to do with US
India, US paving way for free, prosperous Indo-Pacific: Envoy Garcetti
US Defence Secretary lauds Indian Navy's role in anti-piracy operations